In:
RETINAL Cases & Brief Reports, Ovid Technologies (Wolters Kluwer Health), Vol. 12, No. 4 ( 2018), p. 307-309
Abstract:
To report a case of acute retinal necrosis in a patient on anti–tumor necrosis factor α immunosuppressive therapy. Methods: Case report. Results: A 47-year-old man with psoriasis presented with blurred vision and floaters in the left eye 4 days after receiving his fourth dose of adalimumab, a tumor necrosis factor α antagonist. He was diagnosed with acute retinal necrosis and was treated with intravenous acyclovir as well as prophylactic laser barricade. Seven years later, he is 20/20 with no history of a retinal detachment. Conclusion: Physicians prescribing tumor necrosis factor α antagonist immunosuppressive therapy should be aware of the potential of developing acute retinal necrosis.
Type of Medium:
Online Resource
ISSN:
1935-1089
DOI:
10.1097/ICB.0000000000000499
Language:
English
Publisher:
Ovid Technologies (Wolters Kluwer Health)
Publication Date:
2018
